Biote Corp. (BTMD): Valuation
TTM figures as of June 30, 2026
Biote Corp. trades at 6.5 times trailing earnings and a 52.10% free-cash-flow yield. On P/E that is higher than 39% of its own month-end history back to 2022. The Healthcare median P/E is 22.9.
Earnings yield 15.35%. Shareholder yield 18.43%. ROIC 18.3%. Net debt $113.8M.
51 month-end valuation observations are on file, starting June 2022.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is BTMD cheap versus its own history?
Biote Corp. trades at 6.5 times trailing earnings and a 52.10% free-cash-flow yield. On P/E that is higher than 39% of its own month-end history back to 2022. The Healthcare median P/E is 22.9.
What is BTMD's free-cash-flow yield?
Biote Corp. currently yields 52.10% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.